RNAGene

RNAGene Inc. is a new drug research and development company based on mRNA technology. RNAGene has developed its own mRNA-LNP platform, with advantages in ORF and UTR optimization, and is developing preventive and therapeutic vaccines, tumor drugs, etc. In addition to mRNA technology, RNAGene also owns a patented bispecific antigen technology using existing antibodies, named SCALUTIS (Soluble Chimeric Antigen Ligand using Trained Immune System), and aims to develop first-class drugs.